Colorectal Cancer Equity Foundation’s Post

In case you missed it, the U.S. Food and Drug Administration recently approved Guardant Health's Shield, a new blood test for screening #ColorectalCancer (CRC). This is a significant development, as CRC is one of the most common cancers and is rising among younger people. It’s now the leading cause of cancer deaths in men under 50 & the second-leading cause in women. By 2030, it’s projected to be the number one cause of cancer death for both men and women under 50 as well. When caught early, CRC is often treatable. But too many cases are diagnosed in later stages, when treatment is harder, and the chances of survival decrease. That’s why early detection is so crucial. "This new blood test is a game changer, especially for those between 45-49, people with disabilities, & those in underserved and rural communities. With limited colonoscopy availability & ongoing disparities in colorectal cancer screening, having a non-invasive option that does not involve handling stool could dramatically increase screening rates & save lives. This is an exciting and much-needed step forward in expanding access to life-saving screenings for everyone,” says Colorectal Cancer Equity Foundation's Founder & President Dr. Charles R. Rogers. Let's us know your thoughts in the comments & learn more here via NBC News: https://lnkd.in/e2u3Quyq #CRCequity #EarlyDetection #HealthEquity #FDAApproved #ColorectalCancerAwareness #HealthcareInnovation #RuralHealth #HealthForAll #ScreeningSavesLives

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics